Top Page
Plus Therapeutics
(NASDAQ:PSTV)
Plus Therapeutics (PSTV) vs. SPDR S&P 500 ETF (SPY)
Plus Therapeutics Business Overview & Revenue Model
Plus Therapeutics Earnings Call Summary
Plus Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.34M | 5.82M | 4.91M | 224.00K | 0.00 | 303.00K |
| Gross Profit | -616.00K | 4.97M | -4.78M | -488.00K | -66.00K | -2.40M |
| EBITDA | -18.95M | -8.40M | -12.69M | -18.85M | -12.05M | -6.76M |
| Net Income | -27.12M | -12.98M | -13.32M | -20.27M | -13.40M | -8.24M |
Balance Sheet | ||||||
| Total Assets | 12.06M | 6.63M | 11.39M | 23.87M | 21.98M | 12.11M |
| Cash, Cash Equivalents and Short-Term Investments | 9.87M | 3.61M | 8.55M | 18.12M | 18.40M | 8.35M |
| Total Debt | 40.00K | 3.37M | 4.18M | 5.64M | 6.99M | 7.00M |
| Total Liabilities | 35.70M | 15.58M | 12.74M | 17.42M | 11.14M | 9.07M |
| Stockholders Equity | -23.64M | -8.95M | -1.35M | 6.45M | 10.84M | 3.03M |
Cash Flow | ||||||
| Free Cash Flow | -12.87M | -10.70M | -13.01M | -13.48M | -10.42M | -8.93M |
| Operating Cash Flow | -12.21M | -10.55M | -12.85M | -12.97M | -10.28M | -8.43M |
| Investing Cash Flow | -189.00K | -4.11M | -160.00K | -759.00K | -82.00K | -493.00K |
| Financing Cash Flow | 19.37M | 6.19M | 3.44M | 13.45M | 20.42M | -319.00K |
Plus Therapeutics Technical Analysis
Plus Therapeutics Risk Analysis
Plus Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.83B | -0.18 | -40.10% | 2.29% | 21.46% | -2.03% | |
51 Neutral | $13.29M | 0.68 | -162.42% | ― | -82.24% | ― | |
48 Neutral | $50.15M | ― | 249.03% | ― | -3.49% | 27.88% | |
| ― | $11.43M | ― | -2264.31% | ― | ― | ― | |
42 Neutral | $1.52K | ― | ― | -95.23% | 42.16% | ||
34 Underperform | $16.45M | 1.60 | >-0.01% | ― | ― | ― | |
34 Underperform | $19.85M | ― | -9690.24% | ― | 1943.07% | 80.97% |
Plus Therapeutics Corporate Events
On August 22, 2025, Plus Therapeutics, Inc. received confirmation from Nasdaq that it complies with Nasdaq Listing Rule 5550(b), meeting both the Market Value of Listing Securities standard and the alternative stockholders’ equity threshold. This compliance allows the company to extend its grace period to meet the $1.00 bid price rule until November 12, 2025. However, the company is subject to a one-year monitoring period regarding the Equity Standard. If it fails to maintain compliance within this period, Nasdaq will issue a delist determination letter, though the company can request a hearing to potentially stay further actions.
On June 3, 2025, Plus Therapeutics was notified by Nasdaq that it failed to meet the minimum stockholders’ equity requirement of $2.5 million, leading to a delist determination. However, after a hearing on July 15, 2025, the company was granted an extension to comply with the rule. By June 30, 2025, Plus Therapeutics reported stockholders’ equity of $3 million and continued to maintain compliance by selling over $2 million in common stock. The company also reported a market value of listed securities of at least $35 million for 20 consecutive business days as of August 13, 2025, meeting an alternative compliance threshold. Plus Therapeutics is awaiting Nasdaq’s confirmation of compliance with either the equity rule or the alternative market value requirement.
On June 3, 2025, Plus Therapeutics was notified by the Nasdaq Listing Qualifications Department that it failed to meet the minimum stockholders’ equity requirement of $2.5 million, with a reported deficit of $23,641,000 as of March 31, 2025. Consequently, Nasdaq planned to delist the company’s securities unless an appeal was made. Following a hearing on July 15, 2025, the company was granted continued listing on July 22, 2025, provided it meets specific conditions by August 14, 2025, and September 8, 2025, including maintaining a minimum stock price and demonstrating compliance with equity requirements.
On August 7, 2025, Plus Therapeutics held its Annual Meeting of Stockholders where five key proposals were voted on. The stockholders elected directors to the board, approved the potential issuance of up to $51 million in common stock to Lincoln Park Capital Fund, and granted the board authority for a reverse stock split. Additionally, the compensation of named executive officers and amendments to the 2020 Stock Incentive Plan were approved. These decisions reflect strategic moves to strengthen the company’s financial position and operational flexibility.
Plus Therapeutics has entered into a Purchase Agreement with Lincoln Park, which is an accredited investor, to issue and sell securities under exemptions from the registration requirements of the Securities Act. This strategic move allows Plus Therapeutics to raise capital while leveraging regulatory exemptions, potentially impacting its financial strategy and stakeholder interests.
On March 4, 2025, Plus Therapeutics, Inc. entered into a Securities Purchase Agreement with various purchasers, resulting in a private placement involving shares and warrants of the company’s common stock. On June 17, 2025, the company and the purchasers agreed to a letter agreement to minimize the dilutive impact of the private placement. This included the cancellation of Series A Warrants, amendment of Series B Warrants, waiver of the Registration Rights Agreement, and the return of certain shares and warrants by the purchasers. These actions are aimed at reducing the potential negative impact on the company’s stockholders’ equity and facilitating future capital raising efforts.
On June 3, 2025, Plus Therapeutics, Inc. received a letter from Nasdaq stating that the company had regained compliance with Rule 5250(c)(1) after filing its Quarterly Report for the period ended March 31, 2025. However, the company was notified of non-compliance with the Minimum Stockholders’ Equity Requirement, leading to a decision to delist its securities unless an appeal is made. Plus Therapeutics plans to request a hearing to appeal this decision, during which its stock will continue trading on the Nasdaq Capital Market.